Key facts
- It has raised $140K; the latest was Seed Round ($140K) in Apr 2025.
- Notable investors include Hunan Lushan Technology Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Shanling Zhihe
- ·The full record, as it builds
Funding rounds
No funding rounds for Shanling Zhihe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shanling Zhihe
Operator of a biotechnology firm intended to advance molecular diagnostics and personalized medicine. The company offers proprietary gene editing technologies and high-throughput screening capabilities, enabling healthcare institutions and research organizations to improve disease detection and accelerate therapeutic development.
- Sector
- Healthcare
- HQ
- Changsha, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Shanling Zhihe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shanling Zhihe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shanling Zhihe in its N-PORT filings yet. We sweep new filings monthly.